Election committee for Vitrolife AB (publ)

The following people have been appointed as members of Vitrolife’s election
committee for the Annual General Meeting in 2015:
Patrik Tigerschiöld, representing Bure Equity AB
Thomas Olausson
Martin Lewin, representing Eccenovo AB
Carsten Browall, Chairman of the Board

The appointments have been made in accordance with the instructions regarding
principles for the appointment of the company election committee which were
determined at the Annual General Meeting of Vitrolife on May 5, 2014.

The Annual General Meeting of Vitrolife AB (publ) will be held on May 5, 2015 in
Gothenburg.

Shareholders who wish to have an item considered at the Annual General Meeting
can submit a request to the Board to this effect. Such a request for an item to
be considered is to be sent to Vitrolife AB (publ), Att: Chairman of the Board,
Box 9080, 400 92 Gothenburg, and must have been received by the Board no later
than seven weeks before the Annual General Meeting, or otherwise in such good
time that the matter, where necessary, can be included in the notice to attend
the Annual General Meeting.

Gothenburg, October 15, 2014
VITROLIFE AB (publ)
Contact:

Carsten Browall, Chairman of the Board, phone +46 (0)70 255 65 32

Mikael Engblom, CFO, phone +46(0)31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
October 15, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/